CYP2D6 genotype and outcome in tamoxifen treated early breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found no link between CYP2D6 activity and tamoxifen treatment outcomes in early breast cancer patients. Current clinical practices for adjuvant tamoxifen appear effective regardless of genetic variations in CYP2D6 metabolism.
Area Of Science
- Pharmacogenomics
- Oncology
- Clinical Pharmacology
Background
- The clinical significance of CYP2D6 enzyme activity on tamoxifen treatment efficacy in early breast cancer remains unclear.
- Previous studies suggested a link between reduced CYP2D6 activity and poorer outcomes in premenopausal women.
Purpose Of The Study
- To investigate the association between CYP2D6 genotype and clinical outcomes in a larger cohort of tamoxifen-treated early breast cancer patients.
- To determine if CYP2D6 metabolic activity influences recurrence or mortality rates.
Main Methods
- A cohort of 1,103 Swedish breast cancer patients treated with adjuvant tamoxifen (2006-2014) was analyzed.
- CYP2D6 genotype was determined and translated into predicted metabolic activity.
- Cox regression analysis was used to assess the association between CYP2D6 activity and clinical outcomes, controlling for confounders.
Main Results
- No significant association was found between CYP2D6 activity and recurrence or breast cancer mortality in the full cohort.
- Subgroup analyses, including tamoxifen monotherapy, also revealed no significant link between CYP2D6 activity and clinical outcomes.
- The median follow-up was 11.4 years, with 761 patients receiving tamoxifen as monotherapy.
Conclusions
- This study did not find an association between reduced CYP2D6 activity and poorer outcomes in early breast cancer patients treated with tamoxifen.
- The findings suggest that current adjuvant tamoxifen treatment strategies are effective in reducing recurrence risk across different CYP2D6 genotypes in this cohort.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...